The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2009Serum Biomarkers for Parkinson's Disease
Objective/Rationale:
The immune system appears to play an important role in the progression of Parkinson’s disease, and immunotherapy may offer an approach to slow or stop disease progression. The... -
Postural Instability and Gait Disturbances, 2009The Role of White Matter Pathology in the Development of the Postural Instability and Gait Disturbance (PIGD) Type of Parkinson's Disease (PD)-1
Objective/Rationale:
It is not clear why a subset of patients with Parkinson's disease develop postural instability and gait disturbances (PIGD), while others do not. White matter (WM) changes that... -
Rapid Response Innovation Awards, 2009From Anti-aggregation Assay to Treatment for Parkinson's Disease: Developing a Secondary Screen to Bridge High throughput Screen and Cellular Assay
Objective/Rationale:
We want to develop a series of secondary assays that will allow us to shortlist likely drug candidates for therapy against Parkinson’s disease. These assays will bridge the gap... -
Rapid Response Innovation Awards, 2009Investigating the Potential effect of Peroxisome Proliferation in Diminishing Alpha-synuclein Pathogenesis
Objective/Rationale:
Alpha-synuclein is a protein critically involved in the pathogenesis of Parkinson’s disease. Growing evidence link alpha-synuclein pathogenesis in PD and brain lipid metabolism... -
Rapid Response Innovation Awards, 2009Exploring Serotonergic Cortical Targets for Treatment of Parkinson's Disease Using a Mathematical Disease Model
Objective/Rationale:
Because animal models have limited predictability for clinical outcomes of experimental Parkinson drugs, a complex mathematical model of the interactions between key motor... -
Rapid Response Innovation Awards, 2009The Effect of 4-hydroxy-2-nonenal Modification on Alpha-synuclein Toxicity
Objective/Rationale:
Alpha-synuclein is a protein that is normally produced in the human brain. Compelling evidence suggests that alpha-synuclein can acquire a toxic feature that kills dopamine...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.